GlassScriptPhysician profile
Hind Bennani
NPI 1073702213
$864.17
in general payments reported to CMS, 2019-2025
15 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $110 · 2024: $292 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $146.20 | 2024-2025 | Epclusa |
| Sanofi-Aventis U.S. LLC | $124.99 | 2022 | |
| Novo Nordisk INC | $109.52 | 2023 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.99 | 2025 | Caplyta |
| Abbvie INC. | $80.17 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $53.15 | 2024 | Nuzyra |
| Exact Sciences Corporation | $45.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $43.59 | 2024-2025 | Mounjaro, Zepbound |
| Averitas Pharma INC. | $31.31 | 2025 | Qutenza |
| Sage Therapeutics, LLC | $30.15 | 2025 | Zurzuvae |
| Alkermes, INC. | $26.00 | 2024 | Vivitrol |
| Hologic Sales and Service, LLC | $24.56 | 2024 | Thinprep 2000 Processor, Aptima |
| Masimo Corporation | $24.41 | 2024 | Bridge |
| Reprise Biomedical, INC. | $19.09 | 2024 | Miro3d |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hind Bennani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.